Age-Related Macular DegenerationPhase 1NCT01177644
Safety and Preliminary Efficacy Study of PDS-1.0 in Patients With Neovascular AMD
A Phase 1 study testing PDS 1.0 in people with Age-Related Macular Degeneration, run by Forsight Vision4 at 1 site in Israel.
Trial summary
This study will evaluate the safety and preliminary effectiveness of PDS 1.0 in patients with neovascular AMD. Read more about this study
- Who is it for?
- Ages 50 years and older
- Conditions the study is for
- Age-Related Macular Degeneration
- What is being tested?
- PDS 1.0
- Could I receive a placebo?
- No, everyone receives an active treatment
- How many people
- 0 participants
- Where
- 1 siteIsrael
- Study dates
- Jan 2011to Jul 2011
- Phase
- Phase 1
- Are there results?
- None posted in the registry
Key requirements
Who can take part, as listed by the sponsor. Only the study team can confirm whether you are eligible, so take this list to your doctor.
- Ages 50 years and older
- All sexes
- No healthy volunteers
- Adult, Older adult
Who may be able to join
- Diagnosis of CNV secondary to AMD confirmed by fluorescein angiography, not previously treated
- Retinal thickness due to edema of at least 300um in the study eye
- Best corrected visual acuity of 20/80 or worse in the study eye
- Best corrected visual acuity of 20/40 or better in the fellow eye
Who cannot join
- Evidence of scarring CNV (e.g. geographic atrophy) in the study eye
- Fibrosis >75% of lesion area in the study eye
Trial locations and contacts
1 site in 1 country.
About this study
This study will evaluate the safety and preliminary effectiveness of PDS 1.0 in patients with neovascular AMD.
- Conditions
- Age-Related Macular Degeneration
- Being tested
- PDS 1.0
- Medical subject headings
- Macular Degeneration
What participants receive
What participants receive. In a randomised study each person is assigned to one group by chance.
PDS 1.0Drug
| Study group | Role | What they receive |
|---|---|---|
| Active | Experimental | Not described Receives: Drug: PDS 1.0 |
What is being measured
The primary outcome is the main question the study is designed to answer.
Change in retinal thickness measured by Optical Coherence Tomography
Measured: Monthly
Secondary outcomes (1)
Change in Best Corrected Visual Acuity
Measured: Monthly
Timeline
From the start of the study to its completion; the mark is today. Estimated dates are the sponsor’s plan.
- First posted9 Aug 2010 (estimated)
- Study startJan 2011
- Primary completionJul 2011 (estimated)
Resources
- Official record on ClinicalTrials.govThe registry entry this page is built from, with its full change history.
- Other trials for Age-Related Macular DegenerationStudies of the same condition, open and under way.
- What the trial phases meanHow a treatment moves from first tests in people to approval.
More details
For doctors and researchers: how the study is designed, who runs it, and its registry IDs.
Study design
- Study type
- Interventional
- Phase
- Phase 1
- Primary purpose
- Treatment
- Allocation
- Not applicable
- Intervention model
- Single group
- Masking
- None (open label)
- Enrolment
- 0 participants (actual)
Sponsor and investigators
- Lead sponsor
- Forsight Vision4
- Sponsor type
- Industry (pharma, biotech, devices)
- Responsible party
- Sponsor
IDs, dates and publications
- ClinicalTrials.gov ID
- NCT01177644
- Sponsor's protocol ID
- FSV4 FH-1
- Status last verified
- Aug 2012
- First submitted
- 5 Aug 2010
- Last updated
- 22 Aug 2012
- Results posted
- No
Study at a glance
From the registry record, last updated by the sponsor on 22 Aug 2012. Recruitment status is as the sponsor reported it: confirm with the study team.
- Official title
- Safety and Preliminary Efficacy Study of PDS-1.0 in Patients With Neovascular AMD
- ClinicalTrials.gov ID
- NCT01177644
- Acronym / sponsor ID
- FSV4 FH-1
- Conditions
- Age-Related Macular Degeneration
- Phase
- Phase 1
- Study type
- Interventional
- Recruitment status
- Withdrawn
- Enrolment
- 0 participants (actual)
- Lead sponsor
- Forsight Vision4Industry (pharma, biotech, devices)
- Study start
- Jan 2011
- Primary completion
- Jul 2011 (estimated)
- First posted
- 9 Aug 2010 (estimated)
- Results
- Not posted in the source record
Clinical summary
The research question as the sponsor registered it. This describes what the study plans to test, not what it found.
This study will evaluate the safety and preliminary effectiveness of PDS 1.0 in patients with neovascular AMD.
Study design
- Primary purpose
- Treatment
- Allocation
- Not applicable
- Intervention model
- Single group
- Masking
- None (open label)
- Number of arms
- 1
| Arm | Type | Receives |
|---|---|---|
| Active | Experimental | Drug: PDS 1.0 |
Who may qualify
- Ages
- 50 years and older
- Sex
- All
- Healthy volunteers
- Not accepted
- Age groups
- Adult, Older adult
Key inclusion criteria (4 listed)
- Diagnosis of CNV secondary to AMD confirmed by fluorescein angiography, not previously treated
- Retinal thickness due to edema of at least 300um in the study eye
- Best corrected visual acuity of 20/80 or worse in the study eye
- Best corrected visual acuity of 20/40 or better in the fellow eye
Key exclusion criteria (2 listed)
- Evidence of scarring CNV (e.g. geographic atrophy) in the study eye
- Fibrosis >75% of lesion area in the study eye
Eligibility is decided by the study team after screening; this overview does not establish that a patient qualifies. Full inclusion and exclusion criteria.
Interventions
| Intervention | Type | Arms |
|---|---|---|
| PDS 1.0 | Drug | Active |
Primary outcome
Change in retinal thickness measured by Optical Coherence Tomography
Time frame: Monthly
1 secondary outcome
Change in Best Corrected Visual Acuity
Time frame: Monthly
Results and safety
The study was withdrawn before enrolling participants, so there are no results.
Research links
- Official record on ClinicalTrials.govLast updated by the sponsor 22 Aug 2012.
Related trials for Age-Related Macular Degeneration
RecruitingPhase 3
A Study of 36-Week Refill Exchanges of Port Delivery System (PDS) With Ranibizumab in nAMD
Neovascular Age-related Macular Degeneration
RecruitingObservational study
Pivotal Trial of an Automated AI-based System for Early Diagnosis and Prediction of Late Age-related Macular Degeneration
Age-related Macular Degeneration (AMD)
Active, not recruitingObservational study
Real World Evidence in China: Faricimab Use in Diabetic Macular Edema, Retinal Vein Occlusion, and Neovascular Age-Related Macular Degeneration (The Farseeing Study)
Diabetic Macular Edema, Neovascular Age-related Macular Degeneration
Active, not recruitingObservational study
Retinal Pigment Epithelium Safety Study For Patients In B4711001
Age Related Macular Degeneration
RecruitingObservational study
National Ophthalmic Genotyping and Phenotyping Network (eyeGENE (Registered Trademark)), Stage 3 - Expansion of DNA and Data Repositories for Rare Inherited Ophthalmic Diseases
Inherited Ophthalmic Diseases, Hypopigmentation Disorder
Referral and contact
AzTrials does not enrol participants or take referrals. Contact the study team or a site listed below; they decide who can take part. This study is not recruiting at the moment.
The record lists no contact. Use the official record to reach the sponsor.
1 site in 1 country: see every site and its status.
Questions about this trial
What is this clinical trial studying?
A Phase 1 study testing PDS 1.0 in people with Age-Related Macular Degeneration, run by Forsight Vision4 at 1 site in Israel.
The full registered description is in the About this study section and the official record.
Who may be eligible to take part?
The sponsor lists 4 inclusion and 2 exclusion criteria. Eligibility is decided by the study team after screening, so read the full criteria and contact a listed site.
Is this clinical trial currently recruiting?
The record says: withdrawn, as of the sponsor's last update on 22 Aug 2012. Status can change between updates, so confirm with the study contact before making plans.
Where is the study taking place?
The record lists 1 site in Israel. Whether a site is taking part right now should be confirmed with that site. See every site.
What are the possible benefits and risks?
They depend on the study and the treatment, and no study can promise a benefit. The study team explains the known risks during informed consent, before anyone joins; the record itself does not list them.
What does this phase mean?
Phase 1 studies test a treatment in a small group of people for the first time or in a new way, mainly to check safety and find the right dose.
Not every study follows the same path, and some studies (observational studies, device studies) have no phase.
Are results available for this study?
The study was withdrawn before enrolling participants, so there are no results.
How can a doctor refer a patient or contact the research team?
The record lists no contact. The official record names the sponsor, who can be asked directly. AzTrials does not enrol participants or take referrals.
What does the primary outcome measure?
Change in retinal thickness measured by Optical Coherence Tomography (time frame: Monthly). It is what the study was designed to measure, not a finding.
Where can I read the original study information?
Does a listing mean the treatment is approved or proven to work?
No. A listing means the study is registered. It does not show that the treatment is safe, works, or is approved by a regulator.
How often is this information updated?
AzTrials copies changed records from ClinicalTrials.gov every night and reloads the whole registry every week. The sponsor last updated this record on 22 Aug 2012.